Design of a New Vaccine Prototype against Porcine Circovirus Type 2 (PCV2), M. hyopneumoniae and M. hyorhinis Based on Multiple Antigens Microencapsulation with Sulfated Chitosan

dc.contributor.authorArrieta-Mendoza, Darwuin
dc.contributor.authorGarces, Bruno
dc.contributor.authorHidalgo, Alejandro A.
dc.contributor.authorNeira, Victor
dc.contributor.authorRamirez, Galia
dc.contributor.authorNeira-Carrillo, Andrónico
dc.contributor.authorBucarey, Sergio A.
dc.date.accessioned2024-07-19T14:07:11Z
dc.date.available2024-07-19T14:07:11Z
dc.date.issued2024-05
dc.descriptionIndexación: Scopus.
dc.description.abstractThis work evaluated in vivo an experimental-multivalent-vaccine (EMV) based on three Porcine Respiratory Complex (PRC)-associated antigens: Porcine Circovirus Type 2 (PCV2), M. hyopneumoniae (Mhyop) and M. hyorhinis (Mhyor), microencapsulated with sulfated chitosan (M- ChS + PRC-antigens), postulating chitosan sulphate (ChS) as a mimetic of the heparan sulfate receptor used by these pathogens for cell invasion. The EMV was evaluated physicochemically by SEM (Scanning-Electron-Microscopy), EDS (Energy-Dispersive-Spectroscopy), Pdi (Polydispersity-Index) and zeta potential. Twenty weaned pigs, distributed in four groups, were evaluated for 12 weeks. The groups 1 through 4 were as follows: 1-EMV intramuscular-route (IM), 2-EMV oral-nasal-route (O/N), 3-Placebo O/N (M-ChS without antigens), 4-Commercial-vaccine PCV2-Mhyop. qPCR was used to evaluate viral/bacterial load from serum, nasal and bronchial swab and from inguinal lymphoid samples. Specific humoral immunity was evaluated by ELISA. M-ChS + PRC-antigens measured between 1.3–10 μm and presented low Pdi and negative zeta potential, probably due to S (4.26%). Importantly, the 1-EMV protected 90% of challenged animals against PCV2 and Mhyop and 100% against Mhyor. A significant increase in antibody was observed for Mhyor (1-EMV and 2-EMV) and Mhyop (2-EMV), compared with 4-Commercial-vaccine. No difference in antibody levels between 1-EMV and 4-Commercial-vaccine for PCV2-Mhyop was observed. Conclusion: The results demonstrated the effectiveness of the first EMV with M-ChS + PRC-antigens in pigs, which were challenged with Mhyor, PCV2 and Mhyop, evidencing high protection for Mhyor, which has no commercial vaccine available.
dc.description.urihttps://www-scopus-com.recursosbiblioteca.unab.cl/record/display.uri?eid=2-s2.0-85194107458&origin=resultslist&sort=plf-f&src=s&nlo=&nlr=&nls=&sid=dbd85ca00ec1299adff19f78e4cdb00d&sot=aff&sdt=cl&cluster=scofreetoread%2c%22all%22%2ct&sl=34&s=AF-ID%2860002636%29+AND+SUBJAREA%28IMMU%29&relpos=6&citeCnt=0&searchTerm=
dc.identifier.citationVaccines Open Access Volume 12, Issue 5 May 2024 Article number 550
dc.identifier.doi10.3390/vaccines12050550
dc.identifier.issn2076393X
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/58601
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.rights.licenseCC BY 4.0 ATTRIBUTION 4.0 INTERNATIONAL
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectchitosan sulphated
dc.subjectheparan sulfate receptors
dc.subjectmicroparticles
dc.subjectmimetic
dc.subjectMycoplama hyopneumoniae
dc.subjectMycoplama hyorhinis
dc.subjectPCV2
dc.subjectPRC
dc.subjectvaccine
dc.titleDesign of a New Vaccine Prototype against Porcine Circovirus Type 2 (PCV2), M. hyopneumoniae and M. hyorhinis Based on Multiple Antigens Microencapsulation with Sulfated Chitosan
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Design-of-a-New-Vaccine-Prototype-against-Porcine-Circovirus-Type-2-PCV2-M-hyopneumoniae-and-M-hyorhinis-Based-on-Multiple-Antigens-Microencapsulation-with-Sulfated-Chitosan.pdf
Tamaño:
2.08 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción: